Raymond James upgraded Oscar Health (OSCR) to Outperform from Market Perform with an $18 price target The stock’s relative valuation is attractive at current levels as the company’s margins recover across the Affordable Care Act exchange market, the analyst tells investors in a research note. Raymond James sees Oscar Health as the “best house in a tough neighborhood.” The firm says the company’s Q4 miss is backwards looking and that its forward-looking outlook is “more supportive.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health price target lowered to $15 from $17 at UBS
- Oscar Health: Overly Optimistic Growth Assumptions and Rising Medical Cost Risks Drive Sell Rating
- Oscar Health Charts Risky Path Toward 2026 Profitability
- Unusually active option classes on open February 10th
- Oscar Health Projects 2026 Growth Despite 2025 Loss